Associated equity: Actinogen Medical
Edison Investment Research has terminated coverage on Actinogen Medical (ACW). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Actinogen Medical — 7 videos in collection
Actinogen Medical is an ASX-listed Australian biotech developing lead asset Xanamem, a brain-penetrant 11beta-HSD1 inhibitor designed to treat cognitive impairment and other symptoms that occurs in chronic neurological diseases.
• Tell us about the company’s approach to treating Alzheimer’s disease?
• Does it offer a cure or mainly symptom management?
• Actinogen’s drug candidate, Xanamem, targets cortisol in the brain. How is this different from systemic targeting?
• Are there any other neurological diseases, characterised by high levels of cortisol in the brain, which you might also focus on?
• What level of data have you collected with Xanamem so far?
• There has been an increased focus on the treatment field for Alzheimer’s disease. How does this affect Actinogen?
• Which milestones should investors focus on in the coming year?
• Are you planning to add further indications in the longer term?